← Back to Search

CAR T-cell Therapy

agenT-797 for Multiple Myeloma

Phase 1

Waitlist Available

Research Sponsored by AgenTus Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up end of study visit (up to 12 months)

Awards & highlights

Study Summary

This trial is testing a new cancer therapy made from a person's own immune cells. The goal is to find out if it is safe and effective.

Eligible Conditions

Relapsed or Refractory Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ end of study visit (up to 12 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~end of study visit (up to 12 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study visit (up to 12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number Of Dose-limiting Toxicities

Number Of Participants With Treatment-related Adverse Events

Secondary outcome measures

Duration Of Clinical Benefit

Duration Of Response (DOR)

Measurement Of Serum Alloantibodies To Major Histocompatibility Complex Class I And II

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Allogeneic iNKT CellsExperimental Treatment1 Intervention

3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days [2 weeks]).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

agenT-797

2021

Completed Phase 2

~40

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

AgenTus Therapeutics, Inc.Lead Sponsor

MiNK TherapeuticsLead Sponsor

2 Previous Clinical Trials

50 Total Patients Enrolled

Medical DirectorStudy DirectorMiNK Therapeutics

2,777 Previous Clinical Trials

8,063,851 Total Patients Enrolled

25 Trials studying Multiple Myeloma

6,985 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Food and Drug Administration greenlit agenT-797 for public use?

"The team at Power assigned agenT-797 a score of 1, as Phase 1 trials are the earliest stages in clinical research and thus have limited evidence for safety and efficacy."

Answered by AI

Is it possible to enlist in this clinical investigation presently?

"According to clinicaltrials.gov, this trial is no longer recruiting patients - the posting was first made on March 29th 2021 and last edited October 21st 2022. However, there are 807 other medical trials that are currently enrolling volunteers."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

2021. "agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04754100.